Oncotelic Therapeutics (OTLC) Net Income towards Common Stockholders (2010 - 2026)
Oncotelic Therapeutics' Net Income towards Common Stockholders came in at $388,147 for Q2 2026, up 39.7% from $277,856 a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Oncotelic Therapeutics reported Net Income towards Common Stockholders of $249.99 million; for FY2025, it came in at $249.3 million.
- Going back by year, Net Income towards Common Stockholders was -$4.52 million in FY2024, -$7.9 million in FY2023, $5.09 million in FY2022 and -$9.39 million in FY2021.
- The five-year range for quarterly Net Income towards Common Stockholders is -$6.76 million (Q2 2023) to $250.37 million (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.83 Bn | 1,078.42 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 610.61 Bn | 529.14 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 500.66 Bn | 473.77 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 354.64 Bn | 309.02 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 291.14 Bn | 255.13 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 254.18 Bn | 227.87 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 229.46 Bn | 184.86 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 190.33 Bn | 164.53 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 167.92 Bn | 114.57 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Oncotelic Therapeutics | 8.28 Mn | 7.42 Mn | - | 388,147.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 388,147.00 |
| Dec 31, 2025 | 250.37 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | 277,856.00 |
| Mar 31, 2025 | -298,716.00 |
| Dec 31, 2024 | -600,934.00 |
| Sep 30, 2024 | -3.30 Mn |
| Jun 30, 2024 | -209,837.00 |
| Mar 31, 2024 | -408,676.00 |
| Dec 31, 2023 | -735,983.00 |
| Sep 30, 2023 | 115,309.00 |
| Jun 30, 2023 | -6.76 Mn |
| Mar 31, 2023 | -525,419.00 |
| Dec 31, 2022 | -5.29 Mn |
| Sep 30, 2022 | -777,935.00 |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | -4.85 Mn |
| Dec 31, 2021 | -1.79 Mn |
| Sep 30, 2021 | -1.56 Mn |
| Jun 30, 2021 | -3.23 Mn |
API Access
Oncotelic Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();